权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MICA: Well-characterised monoclonal antibody-photosensitiser conjugates for the treatment of head and neck cancer

MICA：用于治疗头颈癌的特性良好的单克隆抗体-光敏剂偶联物

基本信息

批准号：
MR/K025422/1
负责人：
Ross Boyle
金额：
$ 92.7万
依托单位：
University of Hull
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2013
资助国家：
英国
起止时间：
2013 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=MR%2FK025422%2F1
关键词：
MICA Well characterised monoclonal antibody

项目摘要

The project involves developing a novel treatment for head and neck cancer. Head and neck cancer represent a number of different diseases including oral cancers and cancers of the oesophagus and larynx. Latest figures show that more than 16,000 cases of these cancers are diagnosed annually in the UK. Current treatments for head and neck cancer can lead to significant loss of quality of life through loss of speech, difficulties eating and drinking and disfigurement. The treatment we propose here, Photodynamic Therapy (PDT), is much milder than surgery or radiotherapy and consists of administering a dye which localises in the tumour. Visible light, without heat, is used to activate the dye inside the cancer and this causes the release of a toxic form of oxygen (singlet oxygen). Singlet oxygen has a very short sphere of activity and if it does not react with a cancer cell component it returns to the normal, non-toxic form of oxygen. If sufficient singlet oxygen is generated within the tumour the cancer can be destroyed. Preliminary results have shown that a monoclonal antibody that targets head and neck cancer can be loaded with PDT dyes to deliver a high dose, and that this has been effective in model systems. We plan, during this project, to accumulate sufficient data to begin a clinical trial of this new treatment for head and neck cancer.

该项目涉及开发一种治疗头颈癌的新疗法。头颈癌代表了许多不同的疾病，包括口腔癌、食道癌和喉癌。最新数据显示，英国每年确诊的此类癌症病例超过1.6万例。头颈癌目前的治疗方法可能会导致严重的生活质量损失，包括语言障碍、饮食困难和毁容。我们在这里提出的治疗方法，光动力疗法(PDT)，比手术或放射治疗温和得多，包括使用一种位于肿瘤中的染料。可见光在不加热的情况下被用来激活癌症内的染料，这会导致有毒形式的氧(单线态氧)的释放。单线态氧的活动范围非常短，如果它不与癌细胞成分反应，它就会返回到正常的、无毒的氧形式。如果肿瘤内产生了足够的单线态氧，癌症就可以被消灭。初步结果表明，针对头颈部癌症的单抗可以负载PDT染料来传递高剂量，这在模型系统中是有效的。我们计划，在这个项目期间，积累足够的数据，开始这种新的头颈癌治疗方法的临床试验。